A cerebrovascular event after single-dose administration of recombinant factor VIIa in a patient with esophageal variceal bleeding.

AKYILDIZ M., Turan I. , Ozutemiz O. , BATUR Y., ILTER T.

Digestive diseases and sciences, cilt.51, ss.1647-9, 2006 (SCI Expanded İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 51 Konu: 9
  • Basım Tarihi: 2006
  • Doi Numarası: 10.1007/s10620-005-9023-y
  • Dergi Adı: Digestive diseases and sciences
  • Sayfa Sayıları: ss.1647-9


Upper gastrointestinal bleeding (UGIB) is a life-threatening complication of cirrhosis that develops from esophageal varices in almost 70% of patients. The mortality rate from the bleeding episodes is reported to be 30% [1-4]. Standard management of UGIB of cirrhotic patients is vasoactive therapy combined with endoscopic procedures such as endoscopic sclerotherapy and band ligation [5]. Currently, it is reported that recombinant activated fVIIa (Novoseven, NovoNordisc) can correct the prothrombin time in decompensated cirrhotic patients and also can be used safely in Child's B and C cirrhotic patients with UGIB [6-8]. Herein, we describe the first case report in the literature of a cerebrovascular event after the administration of a single dose of fVIIa in a cirrhotic patient with esophageal variceal bleeding.